DESTINY-Breast03 Phase 3 Study Results
TDD of EQ-5D-5L VASa
100
80
80
Time to definitive deterioration, %
60
60
40
40
20
20
+ Censor
T-DXd (n = 261)
T-DM1 (n = 263)
+
DESTINY-Breast03
10
Daiichi-Sankyo
Median (95% CI) TDD, months
13.2 (10.1-15.3) HR (95% CI): 0.77 (0.61-0.98)
8.5 (7.3-10.4) P value: 0.0354
++
T
T
01
2
3
4
15
T
5
Patients at risk:
CO
6
F7
7
T
80
9
10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
Time, months
7
6 2 1 10
T-DXD 261 237 204 186 184 169 156 151 141 135 122 112 97 85 74 62 44 30 23 19 12 9 9
T-DM1 263 244 199 176 169 147 124 108 98 77 68 58 40 29 24 18 16 10 8 5 5 2 2 1 0
EQ-5D-5L, EuroQol 5-dimension, 5-level questionnaire; HR, hazard ratio; TDD, time to definitive deterioration; T-DM1, trastuzumab emtansine;
T-DXd, trastuzumab deruxtecan; VAS, visual analog scale.
P values are not adjusted for multiple testing. TDD is defined as a >10-point change from baseline. aVAS of self-rated overall health and quality of life, measured on a scale from 0 to 100.
ESMO BC 2022 #1630 Oral
47View entire presentation